Adial Pharmaceuticals, Inc.

NasdaqCM ADIL

Adial Pharmaceuticals, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD 0.01

Adial Pharmaceuticals, Inc. Revenue Per Share is USD 0.01 for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.00% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

Adial Pharmaceuticals, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 0.00, a 0.00% change year over year.
Adial Pharmaceuticals, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 0.00, a 0.00% change year over year.
Adial Pharmaceuticals, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 0.00, a 0.00% change year over year.
Adial Pharmaceuticals, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 0.00, a 0.00% change year over year.

Key data

Date	Revenue Per Share	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)

NasdaqCM: ADIL

Adial Pharmaceuticals, Inc.

CEO	Mr. Cary John Claiborne MBA
IPO Date	July 27, 2018
Location	United States
Headquarters	1180 Seminole Trail
Employees	4
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Key trends

Past 5 years